Published in Women's Health Weekly, September 22nd, 2005
"To determine if antiangiogenic agents disrupt primate ovarian function, vehicle or a general angiostatic compound (TNP-470), specific antagonists of vascular endothelial growth factor (soluble VEGF receptor-1, sVEGFR-1; anti-VEGF monoclonal antibody, VEGF Ab) and/or an angiopoietin antagonist (Ang-2) were administered to rhesus monkeys: locally via injection into the preovulatory follicle at midcycle or the developing corpus luteum at the midluteal phase; or systemically via subcutaneous injection in the early follicular phase or at midcycle during the natural menstrual cycle," scientists in the United...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly